Related Experiment Videos
Cross-sectional analysis of sexual function after prostate brachytherapy
Georgina Finney1, Anne-Maree Haynes, Peter Cross
1Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, Sydney, New South Wales, Australia.
Urology
|August 16, 2005
Summary
Prostate brachytherapy impacts sexual function, with younger men experiencing better outcomes. Age is a key factor in sexual potency after treatment, alongside side effects like pain and hematospermia.
Area of Science:
- Oncology
- Urology
- Sexual Medicine
Background:
- Prostate brachytherapy is a common treatment for early-stage prostate cancer.
- Assessing long-term sexual function is crucial for patient quality of life.
Purpose of the Study:
- To evaluate sexual function outcomes following iodine-125 seed implantation for prostate cancer.
- To compare sexual function in different age groups post-brachytherapy.
Main Methods:
- Cross-sectional study of 96 sexually active patients treated with iodine-125 brachytherapy.
- Validated questionnaires (Rand 36-Item Health Survey, UCLA Prostate Cancer Index) assessed sexual function.
Main Results:
- No significant correlation between sexual function and time since treatment.
- Pain on orgasm (40%) and hematospermia (17%) were reported side effects.
- Younger patients (<60 years) showed significantly better sexual function than older patients (>60 years).
Conclusions:
- Sexual function varies widely after brachytherapy, independent of time since treatment.
- Age is a significant predictor of sexual function, with younger men faring better.
- Pain on orgasm and hematospermia are notable side effects impacting treatment decisions.